The Paul Manning Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2011
NCT01434862
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

PBM C19 Research, LLC (a COVID-19 research entity of the Paul Manning Foundation) | The Paul Manning Foundation (private)

Active Ingredients

Drugs in Phase 2 Trials (1)

dupilumab (dupixent) (1 trial)

Drugs in Other Trials (1)

pramlintide (symlin) (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2